Experienced in Obsessive-Compulsive Disorder (OCD)

Sigrid Stroobants

Antwerpen, VLG, BE 
Experienced in Obsessive-Compulsive Disorder (OCD)
Antwerpen, VLG, BE 
OverviewLocationsClinical Research

Overview

Sigrid Stroobants practices in Antwerpen, Belgium. Ms. Stroobants is rated as an Experienced expert by MediFind in the treatment of Obsessive-Compulsive Disorder (OCD). Her top areas of expertise are Huntington Disease, Head and Neck Squamous Cell Carcinoma (HNSCC), Dementia, and Obsessive-Compulsive Disorder (OCD).

Her clinical research consists of co-authoring 122 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Obsessive-Compulsive Disorder (OCD).

Gender
Female

Locations

Antwerpen, VLG 2610, Belgium
Other Locations
Wilrijk, VLG, Belgium
Edegem, VLG, Belgium
Leuven, VLG 3000, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Enrollment Status: Completed
Publish Date: March 31, 2025
Intervention Type: Procedure, Drug
Study Drug: T-DM1
Study Phase: Phase 2

122 Total Publications

Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential.
Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential.
Journal: Journal of medicinal chemistry
Published: October 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Stroobants's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile